Progressive Multifocal Leukoencephalopathy Treatment Market Outlook 2024: Exclusive Report By The Business Research Company

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.

The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing digital health and telemedicine, growing adoption of targeted therapy, improved diagnostic tools, growing awareness of progressive multifocal leukoencephalopathy (pml). Major trends in the forecast period include technological advancements in progressive multifocal leukoencephalopathy (pml) treatment, research and clinical trials, early diagnosis and screening, development of new drug therapies.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12864&type=smp

Market Segmentation:
The main types of treatments for progressive multifocal leukoencephalopathy are anti-retroviral therapy, antiviral or anti-John Cunningham virus (JCV), and others. Antiretroviral therapy refers to the combination of medications used to treat infections caused by retroviruses, particularly the human immunodeficiency virus. These are used to indicate HIV or AIDS, organ transplantation, multiple sclerosis, and hematologic malignancies. These can be administered through various routes, including oral, parenteral, and others, and are used by several end-users, such as hospitals, homecare, specialty centers, and others.
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2023 provides data on the global progressive multifocal leukoencephalopathy treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors' revenues, profiles and market shares. The progressive multifocal leukoencephalopathy treatment market report identifies opportunities and strategies based on market trends and leading competitors' approaches.

Major Driver - Impact Of HIV Infection Prevalence On The Progressive Multifocal Leukoencephalopathy (PML) Market
The growing prevalence of human immunodeficiency virus (HIV) infection is expected to propel the growth of the progressive multifocal leukoencephalopathy market going forward. HIV is a retrovirus that attacks the immune system, specifically targeting CD4 cells (also known as T cells), which play a crucial role in helping the body fight infections. Most patients with HIV infection develop PML due to a poor immunological condition indicated by a low CD4 cell count (200/L), the single most significant cause of PML cases worldwide. When a severe HIV-related immune deficit arises, the latent JCV archetype strain in the brain may increase, leading to brain white matter lesions and PML. For instance, in December 2022, according to the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based joint venture of the United Nations for AIDS, 630,000 (480,000-880,000) people died from AIDS-related illnesses and there were 39.0 million [33.1 million-45.7 million] people living with HIV globally. In 2022, 1.3 million [1 million-1.7 million] additional people developed HIV for the first time. Therefore, the growing prevalence of human immunodeficiency virus (HIV) infection is driving the growth of the progressive multifocal leukoencephalopathy market.

Competitive Landscape:
Major players in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Ipsen Pharma, Apotex Inc., Alkermes PLC, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Top Trend - Cellevolve Bio's Breakthrough In PML Treatment
Major companies operating in the advanced multifocal leukoencephalopathy treatment market are increasingly focusing on product innovation to provide reliable products to their customers and to strengthen their market position. For instance, in October 2022, Cellevolve Bio, a US-based clinical company, received FDA (The United States Food and Drug Administration) clearance for an investigational new drug (IND) application and orphan drug designation for CE-VST01-JC. This drug aims to treat progressive multifocal leukoencephalopathy and will be evaluated in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial called ASCEND-JC. The problem seeks to compare CE-VST01-JC to a placebo to see if CE-VST01-JC can decrease or prevent neurological progression in PML patients. CE-VST01-JC is a T-cell therapy that targets the JC virus, the cause of PML. It is a significant moment for the PML community and Cellevolve, as the most considerable cell treatment study in PML history will be ASCEND-JC.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Progressive Multifocal Leukoencephalopathy Treatment Market Characteristics
3. Progressive Multifocal Leukoencephalopathy Treatment Market Trends And Strategies
4. Progressive Multifocal Leukoencephalopathy Treatment Market - Macro Economic Scenario
5. Progressive Multifocal Leukoencephalopathy Treatment Market Size And Growth
…..
27. Progressive Multifocal Leukoencephalopathy Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.